What patents does Novartis hold on trametinib?
Novartis owns the core composition‑of‑matter patents for trametinib, covering the drug’s active ingredient, its chemical formulation, and its use in BRAF‑mutant melanoma and other cancers. Additional patents protect the manufacturing process and specific dosage forms. These patents give Novartis market exclusivity for trametinib and related branded products such as Mekinist. [1]
When do these patents expire?
The primary patents filed in the early 2000s are set to expire in the mid‑2020s, with the last key patent likely ending around 2025–2026. Some patents may be extended by data exclusivity or secondary patents, pushing protection slightly further, but most coverage is expected to lapse by the end of 2026. [1]
How might exclusivity affect biosimilars?
Because trametinib is a small‑molecule drug, the concept of “biosimilars” does not apply. Instead, generic competitors can enter once the patents and exclusivity expire. If Novartis holds additional secondary patents, generic manufacturers may face additional barriers until those expire, which could delay entry of lower‑priced versions. [1]
Are there any patent challenges or litigation?
As of the latest reports, there are no major public litigations challenging Novartis’s trametinib patents. However, generic manufacturers may file for patent invalidity or seek to design around patents once they become available. The landscape could shift if new evidence of prior art emerges. [1]
How does trametinib’s patent situation compare to similar MEK inhibitors?
Other MEK inhibitors, such as selumetinib (Arrythmic) and cobimetinib (Cotellic), also have robust patent portfolios, but their expiration dates vary. Compared to these, trametinib’s patents expire slightly earlier, potentially giving generics a head start if other competitors face later expiry dates. [1]
What are the implications for pricing and access?
During the patent protection period, Novartis sets the price for Mekinist, which can be high given its use in advanced melanoma. Once patents expire, generic competition could lower costs, improving access. However, market dynamics, such as the availability of combination therapies or newer MEK inhibitors, also influence pricing and adoption. [1]
---
Sources
1. https://drugpatentwatch.com/patents/trametinib